Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO)

Q: What does CUSIP 36322Q107 represent in this 13F holders report?

CUSIP 36322Q107 is the security identifier for GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value used to aggregate holder disclosures.

Q: How many institutions held GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value in Q2 2023?

27 institutional investors reported GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 36322Q107

Q2 2023 13F Holders as of 30 Jun 2023

Security type / class: Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
Total 13F shares: 10,195,650
Total 13F value: $25,692,234
Share change: +1,233,042
Put/Call ratio: 5.8%
SEC-reported price per share: $2.52
Number of holders: 27
Value change: +$3,108,586
Number of buys: 12
Number of sells: 9
Shares outstanding: 7,500,000

Security key

36322Q107

Report period

Q2 2023

Institutions

Top holders

GLTO full security history Ownership snapshot Full 13F holder table Chemomab Therapeutics Ltd. SEC filings Chemomab Therapeutics Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

OrbiMed Israel GP Ltd.

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

0/15

Latest evidence

31 Mar 2023

3/4/5 13F Highest disclosed value: $11,704,591 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC has the largest disclosed position value at $11.7M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Disclosed position value Top 5

OrbiMed Israel GP Ltd. $10.11M

ORBIMED ADVISORS LLC $11.7M

Novo Holdings A/S $4.97M

Cormorant Asset Management, LP $2.49M

MAI Capital Management $508.4K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
OrbiMed Israel GP Ltd.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$10,108,146 2,241,274 shares	—	03 Jan 2023
ORBIMED ADVISORS LLC	13F Company 13F	— mixed-class rows	$11,704,591 6,332,211 shares mixed-class rows	—	31 Mar 2023
Novo Holdings A/S	13F Company 13F	— denominator unverified	$4,970,604 2,497,791 shares	—	31 Mar 2023
Cormorant Asset Management, LP	13F Company 13F	— mixed-class rows	$2,488,000 1,308,407 shares mixed-class rows	—	31 Mar 2023
MAI Capital Management	13F Company 13F	— denominator unverified	$508,351 255,453 shares	—	31 Mar 2023
Laurion Capital Management LP	13F Company 13F	— denominator unverified	$379,397 190,652 shares	—	31 Mar 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

10,195,650

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q2 2023 value	Value change	Value Chg %